Perazine

Oral
Psychoses

Dose reduction may be required.

Coma, CNS depression.

Severe liver and kidney dysfunction, phaeochromocytoma, breast cancer, Parkinson's disease, depression, pronounced changes in BP, orthostatic dysregulation, glaucoma, urinary retention, enlarged prostate, intestinal obstruction, history of convulsions, chronic respiratory symptoms, asthma, leukopenia, coronary heart disease, excitation conduction disorders or arrhythmias, blood dyscrasias. Monitor haematological parameters on prolonged use. May impair ability to drive or operate machinery. Pregnancy and lactation.

Acute neuropathy of the superficial nerve fibres after exposure to the sun. Fatigue, haematological disturbances, mood disorders, breast tenderness, galactorrhoea, amenorrhoea, circulatory failure, nosebleeds, photosensitivity, rash, sleep disturbances, anxiety, oedema of the legs, intestinal inflammation.
Potentially Fatal: Severe hepatic impairment (high doses).

Additive CNS depression with sedatives, tranquillisers, alcohol and other CNS depressants. May increase the effects of antihypertensive agents and epinephrine. May reduce effects of guanethidine, clonidine, levodopa. May potentiate the adverse effects of other anticholinergic drugs e.g. TCAs. Extrapyramidal symptoms may be increased.

Description: Perazine is a phenothiazine antipsychotic agent.

Antipsychotics